Veraxa Biotech AG VRXA
Set alert
1.14 USD +0.01 +0.88%
At close · Oct 30
1.12 -0.02 -1.75%
After hours · Oct 30, 4:00 PM ET
1.08 Day range 1.25
0.98 52-week range 24.79
- YTD
- -89.32%
- 1 year
- -89.14%
- Open
- 1.18
- Prev close
- 1.13
- Mkt cap
- 161.20M
- Vol
- 261.43K
- Avg vol
- 256.26K
- EPS
- -0.57
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.25
Financials — quick view
VRXA Revenue — quarterly 23.43K
VRXA Net income — quarterly -75.72M
VRXA EPS — quarterly -4.89
News
- VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
- Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
- VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
- 12 Health Care Stocks Moving In Friday's Intraday Session
- VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
- VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency
- VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
- VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
- VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
- VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
Your note
Sign in to keep a note on VRXA — it syncs with the Stock Master app.